問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2014-07-01 - 2020-12-31
Condition/Disease
Test Drug
Participate Sites3Sites
Recruiting2Sites
Terminated1Sites
2017-03-14 - 2020-11-01
ALK-positive advanced lung cancer
Brigatinib (AP26113)
Participate Sites6Sites
Recruiting5Sites
未分科
Division of Thoracic Medicine
2017-02-17 - 2020-12-17
Crohn’s Disease
Filgotinib
Participate Sites13Sites
Recruiting8Sites
Terminated3Sites
Division of General Internal Medicine
Active Crohn’s Disease
Filgotinib, 100 mg and 200 mg per tablet
Participate Sites14Sites
Recruiting9Sites
2018-06-29 - 2022-06-30
Systemic Lupus Erythematosus
BMS-986165
Participate Sites8Sites
2022-01-01 - 2025-12-31
Participate Sites2Sites
2021-04-01 - 2022-07-31
facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC)
Rapamycin
Participate Sites1Sites
Recruiting1Sites
2022-04-01 - 2025-12-31
Participate Sites5Sites
Not yet recruiting1Sites
Recruiting4Sites
2013-01-01 - 2022-12-31
Not yet recruiting2Sites
Recruiting3Sites
2020-08-31 - 2026-03-31
Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Oregovomab
Recruiting6Sites
全部
